Skip to main content

Advertisement

SpringerLink
Log in

The Role of Estrogen Receptor in Bone Cells

  • The burden of osteoporosis
  • Published:
Clinical Reviews in Bone and Mineral Metabolism Aims and scope Submit manuscript

Abstract

Estrogen is an essential regulator of the skeleton homeostasis during both childhood and adulthood. As a matter of fact, estrogens and selective estrogen receptor modulators are considered essential treatment tools by clinicians to prevent bone fractures in postmenopausal women. All these observations promote a great interest in discovering the mechanisms by which estrogens protect bone. Over the past years, research performed from several groups has established that the osteoprotective effects of estrogens are due to both direct actions on bone cells and indirect effects mediated through bone marrow cells. Experiments performed in humans and animals, in which estrogen receptor deletion was specifically carried out in different bone cells, have allowed unraveling some aspects of the estrogen actions on bone through these cells. This review highlights the current knowledge about the role of estrogens in the RANKL/OPG system, as well as their role in different bone cells and bone marrow cells.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Kumar R, Thompson EB. The structure of the nuclear hormone receptors. Steroids. 1999;64(5):310–9.

    Article  CAS  PubMed  Google Scholar 

  2. Mosselman S, Polman J, Dijkema R. ER beta: identification and characterization of a novel human estrogen receptor. FEBS Lett. 1996;392:49–53.

    Article  CAS  PubMed  Google Scholar 

  3. Britton DJ, Scott GK, Schilling B, Atsriku C, Held JM, Gibson BW, Benz CC, Baldwin MA. A novel serine phosphorylation site detected in the N-terminal domain of estrogen receptor isolated from human breast cancer cells. J Am Soc Mass Spectrom. 2008;19:729–40.

    Article  CAS  PubMed  Google Scholar 

  4. Couse JF, Korach KS. Estrogen receptor null mice: what have we learned and where will they lead us? Endocr Rev. 1999;20:358–417.

    Article  CAS  PubMed  Google Scholar 

  5. Tsai MJ, O’Malley BW. Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu Rev Biochem. 1994;86:451–86.

    Article  Google Scholar 

  6. Manolagas SC, Kousteni S, Chen JR, Schuller M, Plotkin L, Bellido T. Kinase-mediated transcription, activators of nongenotropic estrogen-like signaling (ANGELS), and osteoporosis: a different perspective on the HRT dilemma. Kidney Int Suppl. 2004;91:S41–9.

    Article  CAS  PubMed  Google Scholar 

  7. Manolagas SC, Jilka RL. Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. N Engl J Med. 1995;332(5):305–11.

    Article  CAS  PubMed  Google Scholar 

  8. Jilka RL. Biology of the basic multicellular unit and the pathophysiology of osteoporosis. Med Pediatr Oncol. 2003;41(3):182–5.

    Article  PubMed  Google Scholar 

  9. Sobacchi C, Frattini A, Guerrini MM, Abinun M, Pangrazio A, Susani L, Bredius R, Mancini G, Cant A, Bishop N, Grabowski P, Del Fattore A, Messina C, Errigo G, Coxon FP, Scott DI, Teti A, Rogers MJ, Vezzoni P, Villa A, Helfrich MH. Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL. Nat Genet. 2007;39(8):960–2.

    Article  CAS  PubMed  Google Scholar 

  10. Udagawa N, Takahashi N, Jimi E, Matsuzaki K, Tsurukai T, Itoh K, Nakagawa N, Yasuda H, Goto M, Tsuda E, Higashio K, Gillespie MT, Martin TJ, Suda T. Osteoblasts/stromal cells stimulate osteoclast activation through expression of osteoclast differentiation factor/RANKL but not macrophage colony-stimulating factor: receptor activator of NF-kappa B ligand. Bone. 1999;25(5):517–23.

    Article  CAS  PubMed  Google Scholar 

  11. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Lüthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997;89(2):309–19.

    Article  CAS  PubMed  Google Scholar 

  12. Dallas SL, Prideaux M, Bonewald LF. The osteocyte: an endocrine cell … and more. Endocr Rev. 2013;34(5):658–90.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  13. Xiong J, O’Brien CA. Osteocyte RANKL: new insights into the control of bone remodeling. J Bone Miner Res. 2012;27(3):499–505.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  14. Xiong J, Onal M, Jilka RL, Weinstein RS, Manolagas SC, O’Brien CA. Matrix-embedded cells control osteoclast formation. Nat Med. 2011;17(10):1235–41.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  15. Crane JL, Cao X. Bone marrow mesenchymal stem cells and TGF-β signaling in bone remodeling. J Clin Invest. 2014;124(2):466–72.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  16. Hayden JM, Mohan S, Baylink DJ. The insulin-like growth factor system and the coupling of formation to resorption. Bone. 1995;17(2 Suppl):93S–8S.

    Article  CAS  PubMed  Google Scholar 

  17. Mohan S, Baylink DJ. Insulin-like growth factor system components and the coupling of bone formation to resorption. Horm Res. 1996;45(Suppl 1):59–62.

    Article  CAS  PubMed  Google Scholar 

  18. Tsuji K, Bandyopadhyay A, Harfe BD, Cox K, Kakar S, Gerstenfeld L, Einhorn T, Tabin CJ, Rosen V. BMP2 activity, although dispensable for bone formation, is required for the initiation of fracture healing. Nat Genet. 2006;38(12):1424–9.

    Article  CAS  PubMed  Google Scholar 

  19. Martin TJ, Allan EH, Ho PW, Gooi JH, Quinn JM, Gillespie MT, Krasnoperov V, Sims NA. Communication between ephrinB2 and EphB4 within the osteoblast lineage. Adv Exp Med Biol. 2010;658:51–60.

    Article  CAS  PubMed  Google Scholar 

  20. Zhao C, Irie N, Takada Y, Shimoda K, Miyamoto T, Nishiwaki T, Suda T, Matsuo K. Bidirectional ephrinB2–EphB4 signaling controls bone homeostasis. Cell Metab. 2006;4(2):111–21.

    Article  CAS  PubMed  Google Scholar 

  21. Ota K, Quint P, Ruan M, Pederson L, Westendorf JJ, Khosla S, Oursler MJ. TGF-β induces Wnt10b in osteoclasts from female mice to enhance coupling to osteoblasts. Endocrinology. 2013;154(10):3745–52.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  22. Sims NA, Martin TJ. Coupling the activities of bone formation and resorption: a multitude of signals within the basic multicellular unit. Bonekey Rep. 2014;8(3):481.

    Google Scholar 

  23. Quint P, Ruan M, Pederson L, Kassem M, Westendorf JJ, Khosla S, Oursler MJ. Sphingosine 1-phosphate (S1P) receptors 1 and 2 coordinately induce mesenchymal cell migration through S1P activation of complementary kinase pathways. J Biol Chem. 2013;288(8):5398–406.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  24. Eghbali-Fatourechi G, Khosla S, Sanyal A, Boyle WJ, Lacey DL, Riggs BL. Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest. 2003;111(8):1221–30.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  25. Shevde NK, Bendixen AC, Dienger KM, Wesley Pike J. Estrogens suppress RANK ligand-induced osteoclast differentiation via a stromal cell independent mechanism involving c-Jun repression. PNAS. 2000;97(14):7829–34.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  26. Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Spelsberg TC, Riggs BL. Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology. 1999;140(9):4367–70.

    CAS  PubMed  Google Scholar 

  27. Lindberg MK, Erlandsson M, Alatalo SL, Windahl S, Andersson G, Halleen JM, Carlsten H, Gustafsson JA, Ohlsson C. Estrogen receptor alpha, but not estrogen receptor beta, is involved in the regulation of the OPG/RANKL (osteoprotegerin/receptor activator of NF-kappa B ligand) ratio and serum interleukin-6 in male mice. J Endocrinol. 2001;171(3):425–33.

    Article  CAS  PubMed  Google Scholar 

  28. Reifenstein EC, Albright F. The metabolic effects of steroid hormones in osteoporosis. J Clin Invest. 1947;26(1):24–56.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  29. Jilka RL, Hangoc G, Girasole G, Passeri G, Williams DC, Abrams JS, Boyce B, Broxmeyer H, Manolagas SC. Increased osteoclast development after estrogen loss: mediation by interleukin-6. Science. 1992;257(5066):88–91.

    Article  CAS  PubMed  Google Scholar 

  30. Bellido T, Jilka RL, Boyce BF, Girasole G, Broxmeyer H, Dalrymple SA, Murray R, Manolagas SC. Regulation of interleukin-6, osteoclastogenesis, and bone mass by androgens. The role of the androgen receptor. J Clin Invest. 1995;95(6):2886–95.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  31. Kousteni S, Chen JR, Bellido T, Han L, Ali AA, O’Brien CA, Plotkin L, Fu Q, Mancino AT, Wen Y, Vertino AM, Powers CC, Stewart SA, Ebert R, Parfitt AM, Weinstein RS, Jilka RL, Manolagas SC. Reversal of bone loss in mice by nongenotropic signaling of sex steroids. Science. 2002;298(5594):843–6.

    Article  CAS  PubMed  Google Scholar 

  32. Smith EP, Boyd J, Frank GR, Takahashi H, Cohen RM, Specker B, Williams TC, Lubahn DB, Korach KS. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med. 1994;331(16):1056–61.

    Article  CAS  PubMed  Google Scholar 

  33. Carani C, Qin K, Simoni M, Faustini-Fustini M, Serpente S, Boyd J, Korach KS, Simpson ER. Effect of testosterone and estradiol in a man with aromatase deficiency. N Engl J Med. 1997;337(2):91–5.

    Article  CAS  PubMed  Google Scholar 

  34. Bilezikian JP, Morishima A, Bell J, Grumbach MM. Increased bone mass as a result of estrogen therapy in a man with aromatase deficiency. N Engl J Med. 1998;339(9):599–603.

    Article  CAS  PubMed  Google Scholar 

  35. Writing group for the PEPI trial. Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. JAMA. 1996;276(17):1389–96.

    Article  Google Scholar 

  36. Lindsay R, Gallagher JC, Kleerekoper M, Pickar JH. Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women. J Am Med Assoc. 2002;287:2668–76.

    Article  CAS  Google Scholar 

  37. Lindsay R, Gallagher JC, Kleerekoper M, Pickar JH. Bone response to treatment with lower doses of conjugated estrogens with and without medroxyprogesterone acetate in early postmenopausal women. Osteoporos Int. 2005;16(4):372–9.

    Article  CAS  PubMed  Google Scholar 

  38. Pinkerton JV, Harvey JA, Lindsay R, Pan K, Chines AA, Mirkin S. Archer DF; SMART-5 Investigators. Effects of bazedoxifene/conjugated estrogens on the endometrium and bone: a randomized trial. J Clin Endocrinol Metab. 2014;99(2):E189–98.

    Article  CAS  PubMed  Google Scholar 

  39. Manolagas SC, Kousteni S, Jilka RL. Sex steroids and bone. Recent Prog Horm Res. 2002;57:385–409.

    Article  CAS  PubMed  Google Scholar 

  40. Jilka RL, Takahashi K, Munshi M, Williams DC, Roberson PK, Manolagas SC. Loss of estrogen upregulates osteoblastogenesis in the murine bone marrow. Evidence for autonomy from factors released during bone resorption. J Clin Invest. 1998;101(9):1942–50.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  41. Poli V, Balena R, Fattori E, Markatos A, Yamamoto M, Tanaka H, Ciliberto G, Rodan GA, Costantini F. Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion. EMBO J. 1994;13(5):1189–96.

    CAS  PubMed Central  PubMed  Google Scholar 

  42. Jilka RL, Hangoc G, Girasole G, Passeri G, Williams DC, Abrams JS, Boyce B, Broxmeyer H, Manolagas SC. Increased osteoclast development after estrogen loss: mediation by interleukin-6. Science. 1992;257(5066):88–91.

    Article  CAS  PubMed  Google Scholar 

  43. Ammann P, Rizzoli R, Bonjour JP, Bourrin S, Meyer JM, Vassalli P, Garcia I. Transgenic mice expressing soluble tumor necrosis factor-receptor are protected against bone loss caused by estrogen deficiency. J Clin Invest. 1997;99(7):1699–703.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  44. Kimble RB, Matayoshi AB, Vannice JL, Kung VT, Williams C, Pacifici R. Simultaneous block of interleukin-1 and tumor necrosis factor is required to completely prevent bone loss in the early postovariectomy period. Endocrinology. 1995;136(7):3054–61.

    CAS  PubMed  Google Scholar 

  45. Lorenzo JA, Naprta A, Rao Y, Alander C, Glaccum M, Widmer M, Gronowicz G, Kalinowski J, Pilbeam CC. Mice lacking the type I interleukin-1 receptor do not lose bone mass after ovariectomy. Endocrinology. 1998;139(6):3022–5.

    Article  CAS  PubMed  Google Scholar 

  46. Horowitz MC, Fretz JA, Lorenzo JA. How B cells influence bone biology in health and disease. Bone. 2010;47(3):472–9.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  47. Pacifici R. Role of T cells in ovariectomy induced bone loss—revisited. J Bone Miner Res. 2012;27(2):231–9.

    Article  PubMed  Google Scholar 

  48. Kanematsu M, Sato T, Takai H, Watanabe K, Ikeda K, Yamada Y. Prostaglandin E2 induces expression of receptor activator of nuclear factor-kappa B ligand/osteoprotegrin ligand on pre-B cells: implications for accelerated osteoclastogenesis in estrogen deficiency. J Bone Miner Res. 2000;15(7):1321–9.

    Article  CAS  PubMed  Google Scholar 

  49. Li X, Ominsky MS, Stolina M, Warmington KS, Geng Z, Niu QT, Asuncion FJ, Tan HL, Grisanti M, Dwyer D, Adamu S, Ke HZ, Simonet WS, Kostenuik PJ. Increased RANK ligand in bone marrow of orchiectomized rats and prevention of their bone loss by the RANK ligand inhibitor osteoprotegerin. Bone. 2009;45(4):669–76.

    Article  CAS  PubMed  Google Scholar 

  50. Onal M, Xiong J, Chen X, Thostenson JD, Almeida M, Manolagas SC, O’Brien CA. Receptor activator of nuclear factor κB ligand (RANKL) protein expression by B lymphocytes contributes to ovariectomy-induced bone loss. J Biol Chem. 2012;287(35):29851–60.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  51. Sims NA, Dupont S, Krust A, Clement-Lacroix P, Minet D, Resche-Rigon M, Gaillard-Kelly M, Baron R. Deletion of estrogen receptors reveals a regulatory role for estrogen receptors-beta in bone remodeling in females but not in males. Bone. 2002;30(1):18–25.

    Article  CAS  PubMed  Google Scholar 

  52. Bunting M, Bernstein KE, Greer JM, Capecchi MR, Thomas KR. Targeting genes for self-excision in the germ line. Genes Dev. 1999;13(12):1524–8.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  53. Chagin AS, Sävendahl L. Estrogens and growth: review. Pediatr Endocrinol Rev. 2007;4(4):329–34.

    PubMed  Google Scholar 

  54. Börjesson AE, Lagerquist MK, Liu C, Shao R, Windahl SH, Karlsson C, Sjögren K, Movérare-Skrtic S, Antal MC, Krust A, Mohan S, Chambon P, Sävendahl L, Ohlsson C. The role of estrogen receptor α in growth plate cartilage for longitudinal bone growth. J Bone Miner Res. 2010;25(12):2690–700.

    Article  PubMed  Google Scholar 

  55. Almeida M, Iyer S, Martin-Millan M, Bartell SM, Han L, Ambrogini E, Onal M, Xiong J, Weinstein RS, Jilka RL, O’Brien CA, Manolagas SC. Estrogen receptor-α signaling in osteoblast progenitors stimulates cortical bone accrual. J Clin Invest. 2013;123(1):394–404.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  56. Ikeda K, Tsukui T, Imazawa Y, Horie-Inoue K, Inoue S. Conditional expression of constitutively active estrogen receptor α in chondrocytes impairs longitudinal bone growth in mice. Biochem Biophys Res Commun. 2012;425(4):912–7.

    Article  CAS  PubMed  Google Scholar 

  57. Bartell SM, Han L, Kim HN, Kim SH, Katzenellenbogen JA, Katzenellenbogen BS, Chambliss KL, Shaul PW, Roberson PK, Weinstein RS, Jilka RL, Almeida M, Manolagas SC. Non-nuclear-initiated actions of the estrogen receptor protect cortical bone mass. Mol Endocrinol. 2013;27(4):649–56.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  58. Martin-Millan M, Almeida M, Ambrogini E, Han L, Zhao H, Weinstein RS, Jilka RL, O’Brien CA, Manolagas SC. The estrogen receptor-alpha in osteoclasts mediates the protective effects of estrogens on cancellous but not cortical bone. Mol Endocrinol. 2010;24(2):323–34.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  59. Nakamura T, Imai Y, Matsumoto T, Sato S, Takeuchi K, Igarashi K, Harada Y, Azuma Y, Krust A, Yamamoto Y, Nishina H, Takeda S, Takayanagi H, Metzger D, Kanno J, Takaoka K, Martin TJ, Chambon P, Kato S. Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts. Cell. 2007;130(5):811–23.

    Article  CAS  PubMed  Google Scholar 

  60. Määttä JA, Büki KG, Gu G, Alanne MH, Vääräniemi J, Liljenbäck H, Poutanen M, Härkönen P, Väänänen K. Inactivation of estrogen receptor α in bone-forming cells induces bone loss in female mice. FASEB J. 2013;27(2):478–88.

    Article  PubMed  Google Scholar 

  61. Melville KM, Kelly NH, Khan SA, Schimenti JC, Ross FP, Main RP, van der Meulen MC. Female mice lacking estrogen receptor-alpha in osteoblasts have compromised bone mass and strength. J Bone Miner Res. 2014;29(2):370–9.

    Article  CAS  PubMed  Google Scholar 

  62. Windahl SH, Börjesson AE, Farman HH, Engdahl C, Movérare-Skrtic S, Sjögren K, Lagerquist MK, Kindblom JM, Koskela A, Tuukkanen J, Divieti Pajevic P, Feng JQ, Dahlman-Wright K, Antonson P, Gustafsson JÅ, Ohlsson C. Estrogen receptor-α in osteocytes is important for trabecular bone formation in male mice. Proc Natl Acad Sci USA. 2013;110(6):2294–9.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  63. Kondoh S, Inoue K, Igarashi K, Sugizaki H, Shirode-Fukuda Y, Inoue E, Yu T, Takeuchi JK, Kanno J, Bonewald LF, Imai Y. Estrogen receptor α in osteocytes regulates trabecular bone formation in female mice. Bone. 2014;60:68–77.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Instituto de investigación Sanitaria (IDIVAL), Hospital Universitario Marqués Valdecilla (HUMV), Santander, Spain

    Marta Martín Millán

Authors
  1. Marta Martín Millán
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marta Martín Millán.

Ethics declarations

Conflict of interest

Marta Martín Millán declare that he have no conflict of interest.

Animal/Human studies

This article does not include any studies with human or animal subjects performed by the author.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Martín Millán, M. The Role of Estrogen Receptor in Bone Cells. Clinic Rev Bone Miner Metab 13, 105–112 (2015). https://doi.org/10.1007/s12018-015-9188-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12018-015-9188-7

Keywords

Search

Navigation